EGFR mutations are present in about 40% of GBM patients which confer a proliferative advantage in NSCs and improve tumor cell survival [23, 36, 46] Microglia, the major macrophages of the CNS, are a key component in determining the fate of NSCs and play an important role in the microenvironment in which GBM progresses. Here, EGFR is linked to glioblastoma.